Skip to main content
Evidence: BMitochondrial FunctionLongevityNeuroprotection

Humanin: Benefits, Dosage & FDA Status

Humanin (HN)

A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.

FDA Status

Not FDA-approved — mitochondrial-derived peptide research compound

Typical Dose

Research range: 0.5–1 mg subcutaneous (rare clinical use)

Evidence Grade

BLimited clinical + robust preclinical evidence

Half-Life

~30 minutes (HNG analog has longer half-life)

Routes of Administration

subcutaneous

First Synthesized

2001

Clinics Indexed

5 providers have offered Humanin in our tracked directory.

Mechanism of Action

Encoded by 16S mitochondrial rRNA; binds FPRL1, IGFBP-3, and BAX to modulate apoptosis and metabolism.

Key Reported Benefits

Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade B indicates limited clinical + robust preclinical evidence.

Reported Side Effects

  • Limited human safety data

Contraindications

  • Pregnancy

Commonly Stacked With

Regulatory & Safety Context

FDA status: Not FDA-approved — mitochondrial-derived peptide research compound

This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.

See state-by-state legality: US peptide legality by state →

References

Selected primary literature on Humanin. Full PubMed records linked. Additional citations are available on request.

  1. PubMed PMID 12867591

Last reviewed: 2026-04-30

← Back to all peptides